Table 4.
All-grade toxicity
| Adverse events, n (%) | n | Neutropenia | Sensory neuropathy | Fatigue |
|---|---|---|---|---|
| Visceral dominant metastasis | ||||
| CA012 | ||||
| nab-P 260 mg/m2 q3w | 74 | 56 (76) | 51 (69) | 37 (50) |
| P 175 mg/m2 q3w | 64 | 51 (80) | 37 (58) | 31 (48) |
| CA024 | ||||
| nab-P 300 mg/m2 q3w | 61a | 55 (92) | 49 (80) | 23 (38) |
| nab-P 100 mg/m2 qw 3/4 | 60 | 48 (80) | 38 (63) | 20 (33) |
| nab-P 150 mg/m2 qw 3/4 | 59 | 53 (90) | 49 (83) | 28 (47) |
| Doc 100 mg/m2 q3w | 67b | 65 (100) | 44 (66) | 39 (58) |
| Short DFI | ||||
| CA012 | ||||
| nab-P 260 mg/m2 q3w | 42 | 30 (71) | 30 (71) | 20 (48) |
| P 175 mg/m2 q3w | 30 | 28 (93) | 16 (53) | 15 (50) |
| CA024 | ||||
| nab-P 300 mg/m2 q3w | 20c | 17 (89) | 14 (70) | 9 (45) |
| nab-P 100 mg/m2 qw 3/4 | 21 | 17 (81) | 15 (71) | 6 (29) |
| nab-P 150 mg/m2 qw 3/4 | 14 | 14 (100) | 11 (79) | 4 (29) |
| Doc 100 mg/m2 q3w | 19 | 19 (100) | 15 (79) | 9 (47) |
DFI disease-free interval, Doc docetaxel, nab-P nab-paclitaxel, P paclitaxel, q3w every 3 weeks, qw 3/4 the first 3 of 4 weeks
a60 Patients evaluable for neutropenia
b65 Patients evaluable for neutropenia
c19 Patients evaluable for neutropenia